Literature DB >> 1326946

Activation of neuromedin B-preferring bombesin receptors on rat glioblastoma C-6 cells increases cellular Ca2+ and phosphoinositides.

L H Wang1, J F Battey, E Wada, J T Lin, S Mantey, D H Coy, R T Jensen.   

Abstract

Recent cloning studies confirm the presence of two subtypes of bombesin (Bn) receptors. In contrast to the gastrin-releasing peptide (GRP)-preferring subtype, which has been widely studied, nothing is known about the cellular mechanisms of the neuromedin B (NMB)-preferring subtype, which occurs widely in the central nervous system and gastrointestinal tissues, partially because of the lack of a cell line with functional receptors. In the present study we have investigated Bn receptors on the rat glioblastoma cell line C-6, reported to contain mRNA of the NMB receptor subtype. Binding of 125I-[D-Tyr0]NMB to these cells was time- and temperature-dependent, saturable, reversible, and only inhibited by Bn receptor agonists or antagonists. For Bn receptor agonists the relative potencies were: NMB (1.7 nM) approximately equal to litorin (3 nM) greater than ranatensin (8 nM) greater than Bn (19 nM) greater than neuromedin C (NMC) (210 nM) greater than GRP (500 nM). These relative affinities were almost identical to those for the NMB receptor subtype on rat oesophageal tissue and for Balb 3T3 cells stably transfected with the NMB receptor subtype. These potencies differed from those for the GRP receptor subtype on rat pancreatic acini [Bn approximately equal to litorin (4 nM) greater than ranatensin, NMC, GRP (15-20 nM) much greater than NMB (351 nM)]. The relative potencies of four different classes of Bn receptor antagonists were compared. Results from C-6 tumour cells agreed closely with those for binding to the NMB receptor subtype on rat oesophageal tissue and in Balb 3T3 cells stably transfected with this receptor, and differed markedly from those for binding to the GRP receptor subtype on rat pancreatic acini. Four Bn receptor antagonists had a higher affinity for the GRP subtype ([D-Phe6]Bn-(6-13)ethyl ester (500 x), [D-Phe6][psi 13-14,Cpa14]Bn- (6-14) (70 x) (where psi 13-14 refers to the replacement of the -CONH- peptide bond between Leu13 and Met14 by -CH2NH2) [psi 13-14,Leu14]Bn, [D-Phe6]Bn-(6-13) propylamide (30 x)] and two had a higher affinity for the NMB subtype on C-6 cells and transfected cells ([D-Pro4,D-Trp7,9,10] substance P-(4-11) (9 x) and [Tyr4,D-Phe12]Bn (18 x)]. In C-6 tumour cells, Bn receptor agonists caused an increase in cytosolic Ca2+ and the generation of inositol phosphates. For both responses, NMB was more than 50-fold more potent than GRP. Neither NMB nor GRP increased cyclic AMP. These results demonstrate that the rat glioblastoma cell line C-6 possesses functional NMB-preferring Bn receptors, and agonist occupation activates phospholipase C, thus increasing cytosolic Ca2+ and inositol phosphate formation. Because the interaction of Bn-related peptides with C-6 cell receptors is identical with that reported in other tissues containing the mRNA for the NMB subtype, this cell line should prove useful in exploring further the cellular basis of action of the peptides that interact with this receptor in the central nervous system and various other tissues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1326946      PMCID: PMC1132948          DOI: 10.1042/bj2860641

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  51 in total

1.  Bombesin-like peptides elevate cytosolic calcium in small cell lung cancer cells.

Authors:  T W Moody; A Murphy; S Mahmoud; G Fiskum
Journal:  Biochem Biophys Res Commun       Date:  1987-08-31       Impact factor: 3.575

2.  Neuromedin B and gastrin-releasing peptide mRNAs are differentially distributed in the rat nervous system.

Authors:  E Wada; J Way; A M Lebacq-Verheyden; J F Battey
Journal:  J Neurosci       Date:  1990-09       Impact factor: 6.167

3.  Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells.

Authors:  J F Battey; J M Way; M H Corjay; H Shapira; K Kusano; R Harkins; J M Wu; T Slattery; E Mann; R I Feldman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

4.  Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution.

Authors:  J F Harper; G Brooker
Journal:  J Cyclic Nucleotide Res       Date:  1975

5.  Interaction of colocalized neuropeptides: functional significance in the circadian timing system.

Authors:  H E Albers; S Y Liou; E G Stopa; R T Zoeller
Journal:  J Neurosci       Date:  1991-03       Impact factor: 6.167

6.  des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists, or agonists.

Authors:  L H Wang; D H Coy; J E Taylor; N Y Jiang; J P Moreau; S C Huang; H Frucht; B M Haffar; R T Jensen
Journal:  J Biol Chem       Date:  1990-09-15       Impact factor: 5.157

Review 7.  Progress in the development of potent bombesin receptor antagonists.

Authors:  R T Jensen; D H Coy
Journal:  Trends Pharmacol Sci       Date:  1991-01       Impact factor: 14.819

8.  Bombesin: action on gut hormones and calcium in man.

Authors:  M A Ghatei; R T Jung; J C Stevenson; C J Hillyard; T E Adrian; Y C Lee; N D Christofides; D L Sarson; K Mashiter; I MacIntyre; S R Bloom
Journal:  J Clin Endocrinol Metab       Date:  1982-05       Impact factor: 5.958

9.  Different receptors mediate the action of bombesin-related peptides on gastric smooth muscle cells.

Authors:  C Severi; R T Jensen; V Erspamer; L D'Arpino; D H Coy; A Torsoli; G Delle Fave
Journal:  Am J Physiol       Date:  1991-05

10.  Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides.

Authors:  M J Berridge; R M Dawson; C P Downes; J P Heslop; R F Irvine
Journal:  Biochem J       Date:  1983-05-15       Impact factor: 3.857

View more
  8 in total

Review 1.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

2.  Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.

Authors:  Hirotsugu Uehara; Nieves González; Veronica Sancho; Samuel A Mantey; Bernardo Nuche-Berenguer; Tapas Pradhan; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2011-06-28       Impact factor: 3.750

3.  Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.

Authors:  Nieves González; Samuel A Mantey; Tapas K Pradhan; Veronica Sancho; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2009-05-20       Impact factor: 3.750

Review 4.  International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.

Authors:  R T Jensen; J F Battey; E R Spindel; R V Benya
Journal:  Pharmacol Rev       Date:  2007-11-30       Impact factor: 25.468

5.  Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa.

Authors:  H S Chave; A C Gough; K Palmer; S R Preston; J N Primrose
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

Review 6.  Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.

Authors:  Terry W Moody; Lingaku Lee; Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

7.  Gastrin-releasing peptide receptors in the central nervous system: role in brain function and as a drug target.

Authors:  Rafael Roesler; Gilberto Schwartsmann
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-17       Impact factor: 5.555

8.  GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI.

Authors:  Fan Pu; Jingjuan Qiao; Shenghui Xue; Hua Yang; Anvi Patel; Lixia Wei; Khan Hekmatyar; Mani Salarian; Hans E Grossniklaus; Zhi-Ren Liu; Jenny J Yang
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.